The AP2A2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the AP2A2 gene in HT29 colorectal adenocarcinoma cells. This population provides a diverse loss-of-function model for studying clathrin-mediated endocytosis without clonal selection biases, ideal for receptor signaling research.
The host cell line, HT29, is an adherent epithelial cell line derived from a 44-year-old female with colorectal adenocarcinoma. These cells are widely utilized in intestinal epithelial biology and cancer research, offering well-characterized endocytic pathways and robust receptor trafficking mechanisms. HT29 exhibits active clathrin-mediated endocytosis, making it a suitable background for dissecting AP-2-dependent processes.
AP2A2 encodes the ??-adaptin A subunit of the AP-2 adaptor complex, which orchestrates clathrin-mediated endocytosis at the plasma membrane. Together with AP2B1, AP2M1, and AP2S1, it forms the heterotetrameric core. The complex is recruited to phosphatidylinositol 4,5-bisphosphate-rich domains and activated by Arf6 GTPase and AAK1 kinase. AP2A2 directly engages cargo receptors and recruits clathrin triskelia, while coordinating with accessory factors like Eps15, amphiphysin, and dynamin for vesicle scission. This process internalizes key receptors such as EGFR, TfR, and LDLR, and subsequently modulates downstream MAPK and AKT signaling pathways. AP2A2 also participates in endosomal sorting and recycling, determining whether cargoes are degraded or returned to the cell surface. Disruption of AP2A2 therefore impairs both endocytic uptake and receptor fate decisions.
In colorectal adenocarcinoma, endocytic control of receptor tyrosine kinase and GPCR signaling is frequently dysregulated, contributing to aberrant proliferation and survival. The AP2A2 knockout in HT29 cells provides a model to dissect the functional consequences of impaired clathrin-mediated endocytosis on oncogenic signaling. Loss of AP2A2 may attenuate internalization of growth factor receptors such as EGFR, thereby altering downstream pathway activation and cellular responses to environmental cues.
The AP2A2 knockout HT29 cells enable detailed dissection of endocytic trafficking mechanisms and their impact on receptor signaling in colorectal cancer models. Researchers can evaluate clathrin-dependent internalization kinetics, investigate the role of endocytosis in drug delivery and antibody-drug conjugate processing, and assess how endocytic disruption alters oncogenic signaling. Compatible assays include Western blotting for AP2A2 and cargo receptors, immunofluorescence for AP-2 and clathrin localization, transferrin-uptake assays, EGFR degradation time courses, flow cytometry for surface receptor quantification, and cell proliferation, migration, or invasion assays. For additional product details and technical support, please contact Ascent Research.
